
HIMS & HERS HEALTH (HIMS), a large-cap biotech growth stock, scored 77% on Validea's Quantitative Momentum Investor model, based on Wesley Gray's strategy. While the stock passed core momentum criteria, this 77% rating falls just below the 80% threshold typically indicating 'some interest,' with 'Return Consistency' and 'Seasonality' noted as neutral, suggesting it doesn't fully meet the higher conviction criteria of this specific quantitative momentum approach.
HIMS & HERS HEALTH INC (HIMS), a large-cap growth stock in the Biotechnology & Drugs sector, scores 77% on Validea's Quantitative Momentum Investor model, which is based on the strategy of Wesley Gray. This score, while moderately positive, falls just short of the 80% threshold that the model typically requires to indicate 'some interest' and well below the 90% 'strong interest' level. The stock successfully passed the core 'Twelve Minus One Momentum' criterion, signaling strong intermediate-term relative performance. However, the overall rating was constrained by 'Neutral' assessments for 'Return Consistency' and 'Seasonality'. This specific combination suggests that while HIMS exhibits favorable momentum characteristics, it does not fully meet the model's requirements for a high-conviction position due to a lack of consistent return patterns and the absence of positive seasonal tailwinds.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment